Imfinzi (durvalumab)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Imfinzi (durvalumab)

Manufacturer AstraZeneca
Disease Bladder Cancer
Indication Locally advanced or metastatic urothelial carcinoma
Mode of Action PD-L1 blocking antibody (immunotherapy)
Approval Status FDA approved (USA)
Strength 50 mg/mL

Who is durvalumab for?

Imfinzi (durvalumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
  • have disease progression during or following platinum-containing chemotherapy
  • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [1].

Recommended dose

Complete information about durvalumab dosage and administration can be found here [1].
The standard dosage is:
  • 10 mg per kilogram of body weight as an intravenous infusion over 60 minutes every 2 weeks
  • Dilute prior to intravenous infusion.  
Consult your doctor for personalised dosage.

What is durvalumab and how does it work?

Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used to treat adults with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [2].
Durvalumab is a monoclonal antibody (a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody) — a type of protein that has been designed to recognise and attach to a specific structure, found in certain cells in the body. Durvalumab has been designed to attach to a receptor called PD-1, found on certain cells of the immune system called T cells. Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor and, in this way, switch off the T cells. By attaching to the receptor, durvalumab prevents cancer cells from switching off T cells, thereby increasing the ability of the immune system to kill cancer cells [1].

What is deutetrabenazine's approval status?

Imfinzi (durvalumab) was approved by:
  • FDA (USA) on May 1, 2017 [2]
for locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. The FDA also approved the VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.) as a complementary diagnostic for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue [2].
The approvals were based on a single-arm clinical trial involving 182 patients. The objective response rate (ORR) was 17.0 % (95 % CI: 11.9, 23.3) across the whole cohort; the ORR for patients with high PD-L1 score (95 patients) was 26.3 % (95 % CI: 17.8, 36.4); the ORR for patients with low or negative PD-L1 score (73 patients) was 4.1 % (95 % CI: 0.9, 11.5). The duration of response ranged between  0.9+ to 19.9+ months (median not reached) [1][2].
The most common adverse reactions in at least 15 % of patients were fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, and urinary tract infection. Grade 3 to 4 adverse events were seen in 43 % of patients. Infection and immune-related adverse events such as pneumonitis, hepatitis, colitis, thyroid disease, adrenal insufficiency, and diabetes were also seen with durvalumab [1][2].
References
[1] Summary of Product Characteristics [FDA]: Imfinzi (durvalumab), AstraZeneca, Apr. 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf
[2] FDA.gov: Approved drugs. Durvalumab (Imfinzi). (last update 01/05/2017), cited on: 27/09/2017.
https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555930.htm

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.